SciSparc Operating Expenses 2017-2024 | SPRC

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

SciSparc operating expenses from 2017 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

SciSparc operating expenses from 2017 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$66B
Zoetis (ZTS)	$65.7B
Daiichi Sankyo, - (DSNKY)	$46.5B
Takeda Pharmaceutical (TAK)	$45.7B
BeOne Medicines - (ONC)	$32.7B
Sandoz Group AG (SDZNY)	$27.5B
Summit Therapeutics (SMMT)	$20.8B
Merck (MKKGY)	$15.9B
Shionogi (SGIOY)	$15.1B
United Therapeutics (UTHR)	$13.5B
Neurocrine Biosciences (NBIX)	$12.5B
IPSEN (IPSEY)	$10.4B
Orion OYJ (ORINY)	$10.3B
Madrigal Pharmaceuticals (MDGL)	$7.6B
Corcept Therapeutics (CORT)	$7.5B
Stevanato Group S.p.A (STVN)	$7.3B
Grifols, S.A (GRFS)	$7.3B
Ionis Pharmaceuticals (IONS)	$6.5B
Hikma Pharmaceuticals Plc (HKMPF)	$5.9B
Ono Pharmaceutical (OPHLF)	$5.2B
Soleno Therapeutics (SLNO)	$4.2B
Hypermarcas (HYPMY)	$2.7B
Crinetics Pharmaceuticals (CRNX)	$2.6B
NewAmsterdam Pharma (NAMS)	$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.6B
Catalyst Pharmaceuticals (CPRX)	$2.4B
Centessa Pharmaceuticals (CNTA)	$2.3B
Ocular Therapeutix (OCUL)	$2.1B
Endo (NDOI)	$1.8B
BioCryst Pharmaceuticals (BCRX)	$1.8B